f luoropyrimidine-based preoperative chemoradiotherapy (CRt) followed by total mesorectal excision is considered the current standard in the management of patients with clinically defined locally advanced rectal cancer. Current national Comprehensive Cancer network guidelines recommend chemoradiation for all patients who are at clinical stage ct3/t4. the recent publication of the early surgical end points in the national surgical adjuvant Breast and Bowel Project (nsaBP) R-04 trial comparing preoperative radiation therapy and capecitabine with or without oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil (5-fu) with or without oxaliplatin 1 and presentations of preliminary data 2 raise important points regarding the difficulty of finding an early end point to gauge the efficacy of CRt when evaluating different or novel regimens.
the criterion standard end point in clinical trials of chemotherapy and radiotherapy in rectal cancer remains overall survival (os). although reliable and easy to measure, this end point takes years to observe. however, an alternative early end point, which would provide an earlier accurate assessment of treatment effects, would be useful.
neoadjuvant CRt achieves significant tumor downstaging/downsizing with pathologic complete response (pCR) in ≤30% of patients in some series where early cancers have been included. after completion of CRt, individual series, population studies, and a meta-analysis 3 have all shown that longer intervals up to a maximum of 12 to15 weeks appear associated with an increased chance of achieving a pCR at surgical resection, and, counterintuitively, outcomes may also improve in terms of a significant reduction in 3-year local recurrence rate (1.2% vs 10.5%; p = 0.04). 4 however, further extensions of this interval do not appear to benefit the patient. 5, 6 Patients with rectal cancer who achieve a pCR or near pCR consistently fare better than the patients who fail to do so. 7 in contrast, patients with no evidence of response fare badly. however, how to best define this response/lack of response and which method to use in terms of clinical measurement, imaging, or pathology to measure size, volume, tumor cell density, t-stage and n-stage downstaging, regression, or residual functional activity remain controversial issues.
alternative early study end points are important because rapid methods to define and quantify the clinical use of novel strategies, such as dose escalation of radiotherapy or the integration of new drugs, along with comparing different strategies within clinical trials using CRt would be a major advantage. these end points should be objective, measurable, sensitive, easy to interpret, and clinically relevant, reflecting a tangible benefit to the patient.
in contrast, the currently accepted late end points demand a long period from the end of recruitment to primary efficacy analysis for end points, such as 5-year local recurrence or disease-free survival (Dfs) or os. long-term follow-up has the advantage of capturing long-term late toxic effects and second malignancies, which may differ between treatments when a large proportion of patients are cured. however, this protracted period may also allow patients who fail later in the trial to receive potentially more effective treatments and survive longer. the outcome could therefore relate to the intensity of preoperative radiotherapy or chemoradiation, the use of varying postoperative adjuvant chemotherapy, or the eventual availability of more effective palliative treatments. also, interpatient heterogeneity with diversity in the phenotypic, epigenetic, and gene expression patterns between different rectal cancers and intratumor heterogeneity within the same individual may blur the assessment of efficacy of any treatment.
the international union against Cancer uses a tnm classification to capture the extent of a cancer. there is a process for revising the tnm in the light of new knowledge. 8 however, the pathologic t stage (pt), and the pathologic n stage (pn) both reflect the initial original preoperative stage, but may also be affected/altered/modified by any preoperative therapy if effective when it is given a "y" prefix. as is pointed out, pCR (ie, ypt0 ypn0) captures only a small proportion of the patients and is not discriminatory for prognosis in the group of patients who fail to achieve pCR.
the rate of pCR within a CRt study reflects the initial proportion of early stage cancers, because pCR after 5-fubased CRt is to some extent dependent on stage. in 1 pooled analysis, the rate of pCR was 58% for t1, 28% for t2, 16% for t3, and 12% for t4 cancers. 7 PCR is also largely dependent on the degree of histopathologic sampling, which is infrequently standardized within study protocols, leading to problems with comparing different studies across the literature. if the entire area of scarring is blocked out and examined at multiple levels, then the pCR rate will be significantly lower than if the patients are less intensively sampled.
an analysis of pooled data from 5 large european randomized clinical trials for locally advanced rectal cancer recommended the concept of nomograms to predict outcome. it suggested that 2-year Dfs could be considered as an intermediate end point in future trials, and this is being used in the current united Kingdom national aristotle CRt trial. the nomograms use data from the preoperative assessments and postoperative histology and treatment, and weigh different items with more or less importance. 9 it is likely that a more inclusive composite end point will prove useful in this setting. the potential advantage of a valid early composite end point is that it will not be influenced by the potential variety of postoperative treatments. the disadvantage is that practices for histopathologic reporting vary on both sides of the atlantic and even within europe, although we are rapidly acquiring a common language. if validated, these alternative end points would hopefully enable the sample size of any study to be reduced, along with the duration of the trial. With this in mind, the nsaBP investigators have suggested the neoadjuvant rectal cancer score (naR score) using ultimate pathologic nodal stage (pn) and downstaging of t stage (ie, ct-pt), which they based on relative weights suggested for each item by the nomograms cited above: where ct = clinical t stage (1 through 4), pt = pathologic t stage (1 through 4), and pn = pathologic nodal status (0 through 2). this captures the difference in t staging and the pathologic nodal status (because they accepted that clinical nodal status is not robust). the naR score uses values from 0 to 100 as a pseudocontinuous variable, where higher scores indicate a poorer prognosis, providing a low, intermediate, and high risk of death based on tertiles. it is recommended that analyses based on the score should be stratified by ct. in an analysis using data from the phase iii neoadjuvant nsaBP R-04 trial, the naR score proved better at predicting os than pCR. 2 although others have confirmed that naR can outperform pCR in predicting os, 10 even naR remains an imperfect end point and may not suffice to predict a satisfactory level of the therapeutic efficacy.
in addition, the biology of tumors is heterogeneous and after CRt different intervals may be required to achieve complete clinical response. 11 the timing to best response may be partially dependent on tumor size. 12 for this reason, composite downstaging end points, such as the naR proposed from results of an overall comparison of the clinical and pathologic staging in the nsaBP R-04 trial, may be the best option. 13 all other things being equal, as above, such end points may also depend on both the precision and homogeneity of the timing of assessment, 14 the means used to get there (chemotherapy or radiotherapy), 15 and the quality of mesorectal excision. 16 in the large, neoadjuvant, randomized phase iii CRt trials, the median interval between completion of preoperative CRt and surgery is between 3 and 10 weeks (table 1) . hence, the interval may influence the selection of patients for adjuvant therapy on the basis of pathologic features in the resected specimens and alter the later outcomes. the nsaBP R-04 also performed surgery at 4 to 6 weeks, so their results and the naR scale are consistent with many of the randomized trials. however, ≤10 weeks is often reported among other published nonrandomized clinical trials, and this interval is extending because of the influence of the habr Gama watch-and-wait data. a retrospective analysis of the swedish rectal cancer trial showed that downstaging is observed after short-course preoperative radiotherapy (sCPRt), when the interval to surgery is extended >10 days from the first fraction of radiotherapy. 17 further extension of the interval after sCPRt in surgery to ≥6 weeks allows significant downstaging but probably not to the same extent as long-course chemoradiation. to this end, some have argued that the interval from the start of treatment to the time of surgery should be similar if sCPRt and CRt are to be compared.
in the stockholm iii trial, when the first 400 patients were evaluated there was an increase in downstaging in those patients where the interval to surgery was extended to 8 weeks compared with immediate surgery within 7 to 10 days. 18 the pCR increased from 2% to 13% (p = 0.001). a Dutch retrospective study supports this. 19 however, downstaging, per se, may not influence Dfs or os. 20 the Polish trial and the trans tasman Radiation oncology Group trial demonstrate that the interval to pathologic assessment influences the rate of response. the amount of downstaging and the pCR are very different in sCPRt with immediate surgery and CRt after a delayed interval. the lack of nodal downstaging in the sCPRt arm has no impact on outcome, although it does in the CRt arm. 21 also, the adjuvant Colon Cancer end Points database shows that the surrogacy of Dfs for os is still present but at a much longer timeframe (os at 7 years) 22 with the addition of oxaliplatin to 5-fu-based chemotherapy. the outcomes for a pCR or persistent positive nodes (ypn+) after radiotherapy may be different from the outcomes after CRt. 15 the only published randomized controlled trial comparing 2 different interval lengths is the lyon R90-01 trial of preoperative radiotherapy, which randomized between a short interval or delayed surgery from the completion of radiotherapy (ie, within 2 weeks or 6-8 weeks). this study demonstrated that a longer interval increases the pCR rate. 23, 24 in the Dutch surgical Colorectal audit, patients who underwent preoperative CRt for rectal cancer between 2009 and 2011 were evaluated to determine the influence of the interval between radiotherapy and surgery, which was calculated from the start of radiotherapy. 5 in this study, an interval of 15 to 16 weeks after the start of CRt resulted in the highest pCR rate (18.0%; p = 0.013), with an independent association (hR, 1.63 (95% Ci, 1.20-2.23)). in a recent Polish study, 154 patients were randomly assigned to sCPRt with surgery either 7 to 10 days or 4 to 5 weeks after the end of radiotherapy. 25 more downstaging was seen after a longer interval. hence, several alternative sequencing approaches have been examined.
however, for the naR score to work in future trials, the timing of surgery would have to be identical for every individual patient, and the 2 arms with and without oxaliplatin would have to be compared in terms of their eventual outcomes and be confirmed as similarly prognostic to validate naR as a surrogate end point. for this reason, similar to the prefix "y" used to denote ptn stage after preoperative chemotherapy or radiotherapy, we would propose the use of a novel prefix "d," which is intended to define the timing of surgery in weeks or even refined to days. this "d" defines the precise timing so that downstaging is captured histologically as a snapshot. one option if only chemoradiation is considered is to define the timing in weeks after the completion of surgery. however, if sCPRt and a delay are used, then it may be more appropriate to define the timing from the start or the first fraction of treatment. this could also apply as the "y" prefix does to neoadjuvant chemotherapy alone.
hence, in summary, if we are to more effectively define and compare the benefits of different preoperative therapies, the time has come to be more precise in the reporting of the interval between the start of treatment and surgery. We recommend that individual patients have a "d" prefix denoting the interval between the start of treatment and its assessment, local excision or definitive surgical procedure. this interval should be denoted in days and might vary between 10 and 119 days (eg, ypd10 t2 ypn0 or ypd119 t2 ypn0). thus, the overall trial could be analyzed according to a median/mean d score.
the nsaBP results show that we need to provide a common metric across a range of clinical stages and tumor sizes, reducing the noisy data of a range of measures currently being used in clinical research, which would eventually allow researchers to compare these results both within and across these groups in different studies. the "d" prefix is a first step. 
